{
  "meta": {
    "title": "24_Diseases_Of_Pituitary",
    "url": "https://brainandscalpel.vercel.app/24-diseases-of-pituitary-b5362497.html",
    "scrapedAt": "2025-11-30T06:57:06.966Z"
  },
  "questions": [
    {
      "id": 50963,
      "choices": [
        {
          "id": 236983,
          "text": "Hyperphosphatemia"
        },
        {
          "id": 236984,
          "text": "Hyperkalemia"
        },
        {
          "id": 236985,
          "text": "Hyperuricemia"
        },
        {
          "id": 236986,
          "text": "Hypercalcemia"
        }
      ],
      "text": "All of the following are seen in tumor lysis syndrome except?",
      "unique_key": "Q8060604",
      "question_audio": null,
      "question_video": null,
      "map_id": 34519735,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Hypercalcemia. Tumor lysis syndrome (TLS) is a potentially life-threatening condition that occurs when a large number of tumor cells are destroyed rapidly, releasing their intracellular contents into the bloodstream. This process can cause hyperphosphatemia, hyperkalemia, and hyperuricemia, but hypercalcemia is not typically seen in TLS. In fact, hypercalcemia is usually associated with malignancy itself, especially with tumors producing parathyroid hormone-related protein (PTHrP) or osteolytic lesions, but it is not a hallmark of TLS. Incorrect Answers A. Hyperphosphatemia Hyperphosphatemia is a common feature of tumor lysis syndrome. When tumor cells break down, they release large amounts of phosphate into the bloodstream. The kidneys may struggle to excrete this excess phosphate, leading to high phosphate levels in the blood. This elevated phosphate can also precipitate with calcium, potentially leading to calcium phosphate deposits in various tissues. B. Hyperkalemia Hyperkalemia is another typical feature of tumor lysis syndrome. Potassium is abundant inside cells, and when tumor cells break down, potassium is released into the bloodstream, leading to elevated potassium levels. This can result in cardiac arrhythmias and other complications, making monitoring of potassium levels critical in TLS management. C. Hyperuricemia Hyperuricemia is a classic feature of tumor lysis syndrome. The breakdown of tumor cells releases nucleic acids, which are metabolized into uric acid. Elevated levels of uric acid in the blood can lead to gout, renal failure, or uric acid crystal deposition in the kidneys. The rapid destruction of tumor cells is a primary cause of this elevated uric acid.",
      "correct_choice_id": 236986,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/263221704444387/263221704444387.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/263221704444387/263221704444387.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50964,
      "choices": [
        {
          "id": 236987,
          "text": "Cranipharyngioma"
        },
        {
          "id": 236988,
          "text": "Prolactinoma"
        },
        {
          "id": 236989,
          "text": "Meningioma"
        },
        {
          "id": 236990,
          "text": "SAH"
        }
      ],
      "text": "A 30 year old woman presented with secondary amennorhea for 3 years along with galactorrhea.The most likely her symptoms would be due to:",
      "unique_key": "Q3804217",
      "question_audio": null,
      "question_video": null,
      "map_id": 34046413,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Prolactinoma. This 30-year-old woman presents with secondary amenorrhea (absence of menstruation for at least 3 months) and galactorrhea (abnormal milk production unrelated to childbirth or nursing). These symptoms are most commonly associated with hyperprolactinemia, which is often caused by a prolactinoma. A prolactinoma is a benign tumor of the pituitary gland that secretes excess prolactin, leading to menstrual irregularities (such as secondary amenorrhea) and galactorrhea. Elevated prolactin levels can inhibit the release of gonadotropin-releasing hormone (GnRH), disrupting the normal menstrual cycle and leading to amenorrhea. Treatment often involves medications such as dopamine agonists (e.g., bromocriptine or cabergoline) to reduce prolactin levels and shrink the tumor. Incorrect Answers A. Craniopharyngioma A craniopharyngioma is a benign tumor that arises near the pituitary gland and hypothalamus. Although it can cause endocrine dysfunction due to its proximity to the pituitary gland, it is not typically associated with elevated prolactin levels or galactorrhea. Craniopharyngiomas often present with visual disturbances, headaches, and signs of hypopituitarism (such as growth hormone or thyroid hormone deficiencies), rather than the symptoms of hyperprolactinemia seen in this patient. C. Meningioma A meningioma is a benign tumor that arises from the meninges (the protective layers of the brain and spinal cord). While it can cause neurological symptoms due to pressure on nearby structures, it is not commonly associated with secondary amenorrhea or galactorrhea. Meningiomas are more likely to present with seizures, headaches, and focal neurological deficits, depending on their location. It is unlikely to be the cause of this patient's symptoms. D. SAH (Subarachnoid Hemorrhage) A subarachnoid hemorrhage (SAH) is typically caused by the rupture of an aneurysm or other vascular malformation in the brain, leading to sudden onset of severe headache, nausea, vomiting, and neurological deficits. SAH would not explain secondary amenorrhea or galactorrhea. While SAH can cause hypopituitarism if the pituitary is damaged, this is a rare complication and would not typically present with the symptoms seen in this patient.",
      "correct_choice_id": 236988,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17765831704444642/17765831704444642.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17765831704444642/17765831704444642.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50965,
      "choices": [
        {
          "id": 236991,
          "text": "> 1 cm"
        },
        {
          "id": 236992,
          "text": "> 1.5 cm"
        },
        {
          "id": 236993,
          "text": "> 2 cm"
        },
        {
          "id": 236994,
          "text": "> 2.5 cm"
        }
      ],
      "text": "Pituitary macroadenoma refers to size of tumour –",
      "unique_key": "Q6643426",
      "question_audio": null,
      "question_video": null,
      "map_id": 34372203,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) > 1 cm. A pituitary macroadenoma is defined as a pituitary tumor with a size greater than 1 cm in diameter. These tumors are often classified as macroadenomas (larger than 1 cm) or microadenomas (smaller than 1 cm). Macroadenomas can cause a variety of symptoms depending on their size and location, including visual disturbances due to compression of the optic chiasm and hormonal imbalances due to excess hormone secretion (e.g., prolactin, growth hormone, or ACTH) or hormone deficiencies due to compression of the normal pituitary tissue. Macroadenomas are more likely to require treatment such as surgery or medical therapy compared to smaller microadenomas. Incorrect Answers B. > 1.5 cm While a pituitary tumor greater than 1.5 cm would certainly be classified as a macroadenoma, this is not the standard definition. The official cutoff for a macroadenoma is > 1 cm, and the size of 1.5 cm is not specifically used to define this category. Tumors between 1 cm and 1.5 cm are still considered macroadenomas, so this option is not entirely accurate. C. > 2 cm Although a tumor greater than 2 cm would still be considered a macroadenoma, the 1 cm threshold is the widely accepted cutoff for macroadenomas. Tumors greater than 2 cm are often referred to as giant adenomas, and these are even larger pituitary tumors that may present with more severe symptoms, but the standard definition still relies on the 1 cm size cutoff. D. > 2.5 cm Similar to option C, a tumor greater than 2.5 cm would certainly be classified as a macroadenoma, but it would also fall under the category of giant pituitary adenomas. The definition of a macroadenoma typically refers to any tumor larger than 1 cm, and this cutoff is generally not based on a 2.5 cm threshold.",
      "correct_choice_id": 236991,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38191801704444655/38191801704444655.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38191801704444655/38191801704444655.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50966,
      "choices": [
        {
          "id": 236995,
          "text": "Pitutary stalk compression"
        },
        {
          "id": 236996,
          "text": "Prolactinoma"
        },
        {
          "id": 236997,
          "text": "Antipsychotic and antidepressant drugs"
        },
        {
          "id": 236998,
          "text": "Pregnancy and lactation"
        }
      ],
      "text": "When PRL level is >200 mcg/L the most common cause is ?",
      "unique_key": "Q6929611",
      "question_audio": null,
      "question_video": null,
      "map_id": 34046472,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Prolactinoma. A prolactinoma is the most common cause of elevated prolactin (PRL) levels greater than 200 mcg/L. Prolactin is a hormone produced by the anterior pituitary that is involved in lactation. Prolactinomas are benign tumors of the pituitary gland that cause excess production of prolactin. This leads to elevated prolactin levels in the blood, often greater than 200 mcg/L. Symptoms of prolactinoma include galactorrhea (milk production) in both men and women, and in women, it can also cause secondary amenorrhea, infertility, and decreased libido. Prolactinomas are often diagnosed through blood tests and MRI imaging of the pituitary gland. Incorrect Answers A. Pituitary stalk compression Pituitary stalk compression can also lead to elevated prolactin levels, but prolactin levels rarely exceed 200 mcg/L in this case. The compression of the pituitary stalk can cause a disruption of the inhibitory effect of dopamine on prolactin secretion, which results in mildly elevated prolactin levels. However, this is generally less common and does not typically cause prolactin levels as high as those seen in prolactinomas. C. Antipsychotic and antidepressant drugs Certain medications, particularly antipsychotic drugs (such as dopamine antagonists) and some antidepressants, can lead to mild to moderate elevations in prolactin levels due to their effects on dopamine receptors. However, these medications typically do not cause prolactin levels as high as 200 mcg/L, and the elevations are usually much lower than those seen in prolactinomas. The elevations caused by drugs are also usually reversible upon discontinuation of the medication. D. Pregnancy and lactation Pregnancy and lactation cause physiological increases in prolactin levels due to the hormonal changes that support milk production. However, prolactin levels during pregnancy or lactation typically do not exceed 200 mcg/L, and they are not usually considered pathological. These physiological elevations are a normal response to the hormonal demands of pregnancy and lactation, and no intervention is required unless there is an underlying pathology like a prolactinoma.",
      "correct_choice_id": 236996,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50408361704444669/50408361704444669.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50408361704444669/50408361704444669.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50967,
      "choices": [
        {
          "id": 236999,
          "text": "Pituitary adenoma > 10 mm."
        },
        {
          "id": 237000,
          "text": "A large polymeric prolactin molecule"
        },
        {
          "id": 237001,
          "text": "Pitutarytumor>4 cm with elevated PRL levels"
        },
        {
          "id": 237002,
          "text": "Any size pituitary adenoma with PRL > 1000 mcg/L ."
        }
      ],
      "text": "Macroprolactenemia refers to :-",
      "unique_key": "Q4474550",
      "question_audio": null,
      "question_video": null,
      "map_id": 34685608,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) A large polymeric prolactin molecule. Macroprolactinemia refers to a condition where the prolactin level is elevated due to the presence of macroprolactin, which is a large polymeric form of prolactin. Unlike the monomeric prolactin that is typically secreted by the pituitary gland, macroprolactin is a complex of prolactin bound to immunoglobulin or other proteins. This form of prolactin is biologically inactive and does not lead to the symptoms typically associated with high prolactin levels, such as galactorrhea or amenorrhea. Macroprolactinemia can be detected through specialized assays that differentiate between the monomeric and polymeric forms of prolactin. The presence of macroprolactin can explain falsely high prolactin levels in patients who do not show symptoms of hyperprolactinemia. Incorrect Answers A. Pituitary adenoma > 10 mm This is not the correct definition of macroprolactinemia. Pituitary adenomas that are larger than 10 mm are classified as macroadenomas, and they are a common cause of hyperprolactinemia due to excess prolactin production. However, macroprolactinemia refers specifically to the presence of large polymeric prolactin molecules, not the size of the pituitary adenoma. Macroadenomas can lead to hyperprolactinemia, but they are not directly related to macroprolactin, and their prolactin levels are often higher than in macroprolactinemia. C. Pituitary tumor > 4 cm with elevated PRL levels This option describes a large pituitary tumor, which can certainly lead to elevated prolactin levels (hyperprolactinemia), but it does not specifically refer to macroprolactinemia. Macroprolactinemia is due to the presence of macroprolactin in the blood, not just elevated prolactin levels from a pituitary tumor. A large tumor may lead to hyperprolactinemia because of excess production of prolactin, but this is a different condition than macroprolactinemia, which involves the molecular form of prolactin. D. Any size pituitary adenoma with PRL > 1000 mcg/L While pituitary adenomas can cause elevated prolactin levels greater than 1000 mcg/L, this is not the definition of macroprolactinemia. As explained earlier, macroprolactinemia is specifically caused by macroprolactin (a large polymeric form of prolactin), not simply by high prolactin levels from a pituitary adenoma. The key distinction is that macroprolactinemia involves a biologically inactive form of prolactin, not just an elevation of prolactin levels.",
      "correct_choice_id": 237000,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39478701704444682/39478701704444682.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39478701704444682/39478701704444682.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50968,
      "choices": [
        {
          "id": 237003,
          "text": "Recheck PRL in dilution"
        },
        {
          "id": 237004,
          "text": "Start Cabergoline @ 1 mg per week"
        },
        {
          "id": 237005,
          "text": "Stop Risperidone and measure PRL after 3 days."
        },
        {
          "id": 237006,
          "text": "Switch to an atypical antipsychotic in consultation with her psychiatrist."
        }
      ],
      "text": "A 20 year old woman on risperidone for BPAD presents with amenorrhea and galactorrhea and is found to have an elevated Prolactin(PRL) level 80 mcg/L .What is next best step in her management?",
      "unique_key": "Q8228256",
      "question_audio": null,
      "question_video": null,
      "map_id": 34333495,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Stop Risperidone and measure PRL after 3 days. Risperidone is a second-generation antipsychotic that is associated with elevated prolactin levels. This occurs because risperidone antagonizes dopamine D2 receptors, which normally inhibit prolactin secretion. Elevated prolactin can lead to symptoms like amenorrhea, galactorrhea, and infertility, as seen in this patient. The next best step is to stop the risperidone to assess whether discontinuing the medication normalizes the prolactin levels. Prolactin levels can be checked again after a few days, as prolactin levels tend to drop relatively quickly after stopping the medication. If prolactin levels normalize after discontinuation, the symptoms are likely due to the risperidone and can be managed accordingly. Explanation for Incorrect Options: A. Recheck PRL in dilution: This option is incorrect because while rechecking prolactin levels might be appropriate in certain cases, the most urgent action here is to remove the medication likely causing the elevated prolactin. Diluting prolactin levels is typically used in cases where there is suspicion of assay interference (e.g., hemolysis or macroprolactinemia), which isn't suggested by this patient's presentation. The elevated prolactin level here is most likely due to the antipsychotic, making stopping the medication the priority. B. Start Cabergoline @ 1 mg per week: Cabergoline is a dopamine agonist used to treat hyperprolactinemia. However, in this case, the elevated prolactin is most likely due to risperidone use. Instead of immediately starting cabergoline, it is more appropriate to first discontinue the offending medication (risperidone) and reassess prolactin levels. Cabergoline may be considered later if prolactin remains elevated after stopping the medication, but this step is premature. D. Switch to an atypical antipsychotic in consultation with her psychiatrist: Switching to another atypical antipsychotic may be considered later if necessary, but the first step should be to stop the current medication (risperidone) and evaluate the effect on prolactin levels. Not all antipsychotics cause prolactin elevation to the same extent, and switching medications without evaluating the response to discontinuation of risperidone may not address the root cause of the issue. This should be a subsequent step, not the immediate response.",
      "correct_choice_id": 237005,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56281981704444695/56281981704444695.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56281981704444695/56281981704444695.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50969,
      "choices": [
        {
          "id": 237007,
          "text": "Radiotherapy"
        },
        {
          "id": 237008,
          "text": "Chemotherapy"
        },
        {
          "id": 237009,
          "text": "Bromocryptine"
        },
        {
          "id": 237010,
          "text": "Surgery"
        }
      ],
      "text": "A young women with secondary amenorrhoea ,galactorrhea and bitemporal heminopia .MRI shows a tumor of 25mm diameter in pituitary fossa.Treatment is;",
      "unique_key": "Q7726875",
      "question_audio": null,
      "question_video": null,
      "map_id": 34505494,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Bromocriptine. This young woman presents with secondary amenorrhea, galactorrhea, and bitemporal hemianopia, which are classic signs of a prolactinoma, a type of pituitary tumor that produces excess prolactin. The tumor size of 25mm and the associated symptoms strongly suggest a prolactin-secreting pituitary adenoma. The first-line treatment for a prolactinoma is dopamine agonists like bromocriptine or cabergoline. These medications work by reducing prolactin secretion, shrinking the tumor, and improving symptoms such as amenorrhea and galactorrhea. Bromocriptine is often effective in treating the tumor and alleviating associated visual symptoms (like bitemporal hemianopia) by reducing the size of the tumor. Explanation for Incorrect Options: A. Radiotherapy: Radiotherapy is typically reserved for patients who do not respond to medical treatment with dopamine agonists or for those who cannot tolerate these medications. It is not the first-line therapy for prolactinomas, especially in a patient who can be treated effectively with bromocriptine. Radiotherapy can have long-term side effects, so it is only considered when other treatment options have failed. B. Chemotherapy: Chemotherapy is not a standard treatment for prolactinomas. Prolactinomas are generally responsive to medical therapies such as dopamine agonists (bromocriptine or cabergoline). Chemotherapy is typically used for malignancies or tumors that are not responsive to other treatments, but it is not applicable in the treatment of benign prolactin-secreting tumors. D. Surgery: Surgery may be considered if the prolactinoma does not respond to dopamine agonist therapy, if the patient has severe visual impairment, or if the tumor is particularly large and causing significant pressure on surrounding structures. However, surgery is typically not the first-line treatment for prolactinomas because medical therapy with dopamine agonists is effective in most cases. Surgery is generally reserved for cases where medical treatment fails or is not an option.",
      "correct_choice_id": 237009,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8248071704444708/8248071704444708.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8248071704444708/8248071704444708.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50970,
      "choices": [
        {
          "id": 237011,
          "text": "Most common tumors in pregnancy and are usually asymptomatic"
        },
        {
          "id": 237012,
          "text": "The size of the tumor increases in pregnancy"
        },
        {
          "id": 237013,
          "text": "Increasing prolactin levels indicates bad prognosis/requires monitoring"
        },
        {
          "id": 237014,
          "text": "In macroadenomas of 1cm may lead to optic chiasma compression"
        }
      ],
      "text": "True about Prolactinoma in pregnancy are all except:",
      "unique_key": "Q1012449",
      "question_audio": null,
      "question_video": null,
      "map_id": 34758417,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Increasing prolactin levels indicates bad prognosis/requires monitoring. During pregnancy, prolactin levels naturally increase to prepare for lactation, and this physiological increase can complicate the interpretation of prolactin levels. Prolactinoma patients typically already have elevated prolactin levels, but an increase in prolactin during pregnancy does not necessarily indicate a worsening of the tumor or a poor prognosis. Rather, the increase in prolactin is a normal physiological response to pregnancy. Therefore, simply seeing higher prolactin levels during pregnancy does not automatically indicate a need for more intense monitoring or suggest a bad prognosis. Prolactin levels should be interpreted in the context of pregnancy, and treatment decisions should be made based on symptoms and tumor growth rather than just prolactin levels. Explanation for Incorrect Options: A. Most common tumors in pregnancy and are usually asymptomatic: Prolactinomas are indeed the most common pituitary tumors found during pregnancy. They are usually asymptomatic or only mildly symptomatic in many cases. Most prolactinomas in pregnancy do not cause significant problems, and patients can usually manage them without any major complications. Symptoms tend to be stable during pregnancy due to hormonal changes, but they can worsen in some individuals, especially with large tumors. B. The size of the tumor increases in pregnancy: The size of prolactinomas can indeed increase during pregnancy. The increased levels of estrogen during pregnancy may stimulate tumor growth, and this can cause symptoms such as headaches, visual disturbances, and in some cases, optic chiasm compression. Close monitoring of the tumor size is important, particularly for larger tumors, to detect any potential complications. D. In macroadenomas of 1 cm may lead to optic chiasma compression: This is true. In cases of macroadenomas (tumors greater than 1 cm), there is a risk of compression of surrounding structures like the optic chiasm, leading to visual disturbances, such as bitemporal hemianopia. These larger tumors may need closer monitoring, especially if symptoms such as visual changes or headaches arise during pregnancy.",
      "correct_choice_id": 237013,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27561931704444722/27561931704444722.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27561931704444722/27561931704444722.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50971,
      "choices": [
        {
          "id": 237015,
          "text": "Induction of delivery"
        },
        {
          "id": 237016,
          "text": "Start bromocriptine therapy."
        },
        {
          "id": 237017,
          "text": "Urgent neurosurgical intervention"
        },
        {
          "id": 237018,
          "text": "Urgent radiotherapy"
        }
      ],
      "text": "8 months pregnant female with past history of prolactinoma presents with headache and no visual impairement .Which of the following is the most appropriate immediate step in her management :-",
      "unique_key": "Q3224706",
      "question_audio": null,
      "question_video": null,
      "map_id": 34892142,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Start bromocriptine therapy. In this case, the patient is 8 months pregnant and has a history of prolactinoma, presenting with a headache. While the headache could be a symptom of tumor growth, it’s important to first address the potential underlying cause. The most appropriate step is to start bromocriptine therapy. Bromocriptine is a dopamine agonist that can reduce the size of prolactinomas, lower prolactin levels, and alleviate symptoms like headaches. It is considered safe to use during pregnancy, although it is typically reserved for cases where the tumor is causing symptoms. In this case, the patient has no visual impairment, which suggests that the tumor is not yet causing severe neurological compression. Therefore, starting bromocriptine would help manage the prolactinoma and potentially reduce the headache by shrinking the tumor or lowering prolactin levels. Explanation for Incorrect Options: A. Induction of delivery: Inducing delivery in this case is not indicated because the patient is only 8 months pregnant, and she is not experiencing severe complications like fetal distress or life-threatening issues related to the tumor. The headache is not an immediate indication for delivery, and managing the prolactinoma first is the better approach. Premature delivery could introduce unnecessary risks for both the mother and the baby. C. Urgent neurosurgical intervention: Urgent neurosurgical intervention would be considered if the patient were experiencing severe neurological symptoms, such as significant visual impairment (e.g., bitemporal hemianopia) or other signs of optic chiasm compression, which is not the case here. Surgery is generally reserved for large prolactinomas that do not respond to medical treatment or when there are complications that require immediate attention. In this case, the patient does not have visual deficits, making urgent surgery unnecessary. D. Urgent radiotherapy: Radiotherapy is typically used for prolactinomas that are resistant to medical treatment or when surgery is not an option. It is not the first-line treatment and is not indicated in this case, especially since there is no indication of rapid tumor growth or compression of critical structures. Starting medical therapy with bromocriptine would be a more appropriate first step.",
      "correct_choice_id": 237016,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6967081704444734/6967081704444734.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6967081704444734/6967081704444734.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50972,
      "choices": [
        {
          "id": 237019,
          "text": "Reduced vertebral bone density"
        },
        {
          "id": 237020,
          "text": "Decreased libido"
        },
        {
          "id": 237021,
          "text": "Weight loss."
        },
        {
          "id": 237022,
          "text": "Hirsutism"
        }
      ],
      "text": "Which of the following is not a presenting feature of hyperprolactinemia in women ?",
      "unique_key": "Q4732987",
      "question_audio": null,
      "question_video": null,
      "map_id": 34279443,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Weight loss. Hyperprolactinemia in women is most commonly associated with symptoms related to reproductive and endocrine dysfunction, not weight loss. In fact, weight gain rather than weight loss is often observed in women with elevated prolactin levels, as prolactin can influence metabolism and increase appetite. Weight loss is not a typical presenting feature of hyperprolactinemia, making it the correct choice as the exception. Explanation for Incorrect Options: A. Reduced vertebral bone density: This is a common presenting feature of hyperprolactinemia. Elevated prolactin levels can inhibit the secretion of gonadotropin-releasing hormone (GnRH), leading to a decrease in estrogen levels. Reduced estrogen levels, in turn, can lead to bone demineralization and a higher risk of osteoporosis, including reduced vertebral bone density. B. Decreased libido: Decreased libido is a common symptom in women with hyperprolactinemia. High prolactin levels suppress gonadal function, leading to a decrease in estrogen and progesterone, which can lower sexual desire and cause other sexual dysfunctions. D. Hirsutism: Hirsutism, or excessive hair growth in a male pattern, can also be seen in women with hyperprolactinemia, especially if the hyperprolactinemia is associated with other hormonal imbalances, such as those seen in polycystic ovary syndrome (PCOS). Elevated prolactin levels can lead to a disturbance in the balance of sex hormones, potentially resulting in hirsutism.",
      "correct_choice_id": 237021,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/32371131704444748/32371131704444748.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/32371131704444748/32371131704444748.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50973,
      "choices": [
        {
          "id": 237023,
          "text": "Peak serum PRL levels occur between 4-6 A.M"
        },
        {
          "id": 237024,
          "text": "Circulating half life of PRL is 50 minutes."
        },
        {
          "id": 237025,
          "text": "Predominant central control mechanism is inhibitory."
        },
        {
          "id": 237026,
          "text": "None of the above."
        }
      ],
      "text": "Which of the following is false about prolactin ?",
      "unique_key": "Q6909736",
      "question_audio": null,
      "question_video": null,
      "map_id": 34212519,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) None of the above, which means all the statements about prolactin (PRL) are true. Let's analyze each statement: A. Peak serum PRL levels occur between 4-6 A.M. This is true. Prolactin secretion follows a circadian rhythm, with peak levels occurring during sleep, particularly between 4-6 A.M. B. Circulating half-life of PRL is 50 minutes. This is also true. The half-life of prolactin in circulation is approximately 50 minutes. C. Predominant central control mechanism is inhibitory. This is correct. Prolactin secretion is primarily under inhibitory control by dopamine, which acts as the main prolactin-inhibiting factor (PIF).",
      "correct_choice_id": 237026,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58708361704444760/58708361704444760.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58708361704444760/58708361704444760.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50974,
      "choices": [
        {
          "id": 237027,
          "text": "Insulin like activity"
        },
        {
          "id": 237028,
          "text": "Protein synthesis"
        },
        {
          "id": 237029,
          "text": "Lipolytic"
        },
        {
          "id": 237030,
          "text": "Epiphyseal growth"
        }
      ],
      "text": "Which of the following is not action of IGF-1 :-",
      "unique_key": "Q2855942",
      "question_audio": null,
      "question_video": null,
      "map_id": 34660927,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Insulin-like Growth Factor 1 (IGF-1) has various actions, primarily associated with growth and metabolic effects. Here's an analysis of the options: A. Insulin-like activity: True. IGF-1 has insulin-like activity, particularly in promoting glucose uptake in certain tissues and reducing blood glucose levels, though its potency is much less than insulin. B. Protein synthesis: True. IGF-1 stimulates protein synthesis, which is critical for muscle growth and repair. C. Lipolytic: False. IGF-1 is not lipolytic. Instead, it generally has anabolic effects, promoting fat storage rather than breaking down fat. Lipolysis is more associated with hormones like glucagon, adrenaline, and cortisol. D. Epiphyseal growth: True. IGF-1 plays a crucial role in stimulating epiphyseal (long bone) growth during childhood and adolescence, largely by promoting chondrocyte proliferation and bone matrix production.",
      "correct_choice_id": 237029,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29864031704444774/29864031704444774.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29864031704444774/29864031704444774.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50975,
      "choices": [
        {
          "id": 237031,
          "text": "Levels peak at 16 years of age"
        },
        {
          "id": 237032,
          "text": "Higher in males than in females."
        },
        {
          "id": 237033,
          "text": "Levels low in sepsis"
        },
        {
          "id": 237034,
          "text": "Levels high in acromegaly"
        }
      ],
      "text": "Which of the following about serum IGF-1 concentration is false ?",
      "unique_key": "Q7774054",
      "question_audio": null,
      "question_video": null,
      "map_id": 34876756,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Higher in males than in females. Serum IGF-1 levels are not consistently higher in males than in females. The levels of IGF-1 depend on several factors, including age, sex, and hormonal regulation. While IGF-1 levels peak during puberty and are influenced by growth hormone (GH), females often exhibit slightly higher levels during adolescence compared to males. This is largely due to differences in hormonal activity during puberty. Reasons for Correct and Incorrect Options: A. Levels peak at 16 years of age – Correct: Serum IGF-1 levels peak during adolescence, typically around the age of 16. This coincides with the peak in growth hormone secretion during puberty, which drives IGF-1 production in the liver and peripheral tissues. These high levels support the rapid growth and anabolic processes associated with puberty. After this peak, IGF-1 levels gradually decline with age. C. Levels low in sepsis – Correct: In sepsis, IGF-1 levels are significantly reduced due to suppressed growth hormone receptor expression and hepatic dysfunction. This decrease in IGF-1 levels contributes to the catabolic state often seen in critically ill patients, as IGF-1 plays a key role in promoting protein synthesis and reducing protein breakdown. D. Levels high in acromegaly – Correct: Acromegaly is characterized by excessive secretion of growth hormone, leading to abnormally high levels of IGF-1. Elevated IGF-1 levels are a hallmark of the condition and are used diagnostically to assess disease severity and monitor treatment response.",
      "correct_choice_id": 237032,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26150131704444787/26150131704444787.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26150131704444787/26150131704444787.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50976,
      "choices": [
        {
          "id": 237035,
          "text": "GH suppression test."
        },
        {
          "id": 237036,
          "text": "GH assay"
        },
        {
          "id": 237037,
          "text": "Insulin stimulation test."
        },
        {
          "id": 237038,
          "text": "IGF levels"
        }
      ],
      "text": "Confirmatory investigation for acromegaly",
      "unique_key": "Q8454752",
      "question_audio": null,
      "question_video": null,
      "map_id": 34252547,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) GH suppression test. The confirmatory investigation for acromegaly is the Growth Hormone (GH) suppression test, also known as the oral glucose tolerance test (OGTT) for GH suppression. This test evaluates whether growth hormone levels can be suppressed by oral glucose. In healthy individuals, GH levels decrease to less than 1 ng/mL after a glucose load, whereas in acromegaly, GH levels remain elevated or fail to suppress adequately. This test is considered the gold standard for confirming the diagnosis of acromegaly. Reasons for Correct and Incorrect Options: A. GH suppression test – Correct: The GH suppression test is a definitive diagnostic test for acromegaly because it assesses the inability of glucose to suppress GH secretion, which is a hallmark of the disease. Patients with acromegaly have autonomous GH secretion that is resistant to the normal feedback inhibition by glucose. This test is reliable, specific, and widely used in clinical practice to confirm the diagnosis. B. GH assay – Incorrect: While a random GH assay can detect elevated levels of GH, it is not confirmatory because GH secretion is pulsatile and influenced by various physiological factors, such as stress, exercise, and sleep. A single elevated GH level may not reliably indicate acromegaly. Therefore, it lacks specificity for diagnosis. C. Insulin stimulation test – Incorrect: The insulin stimulation test is not used for diagnosing acromegaly. Instead, it is primarily used to evaluate growth hormone deficiency by stimulating GH secretion with hypoglycemia. This test is irrelevant in the context of diagnosing acromegaly. D. IGF levels – Incorrect: Although IGF-1 levels are elevated in acromegaly and are a useful screening tool, they are not confirmatory. IGF-1 levels reflect the integrated secretion of GH and are used for initial assessment and monitoring of treatment. However, IGF-1 elevation alone cannot definitively confirm acromegaly, as other conditions (e.g., liver disease or malnutrition) can also affect IGF-1 levels.",
      "correct_choice_id": 237035,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21850001704444799/21850001704444799.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21850001704444799/21850001704444799.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50977,
      "choices": [
        {
          "id": 237039,
          "text": "Mental retardation"
        },
        {
          "id": 237040,
          "text": "Visceromegaly"
        },
        {
          "id": 237041,
          "text": "Large foot"
        },
        {
          "id": 237042,
          "text": "Cardiovascular damage"
        }
      ],
      "text": "All are seen in Gigantism except :-",
      "unique_key": "Q5479675",
      "question_audio": null,
      "question_video": null,
      "map_id": 34714351,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Mental retardation. Mental retardation is not a typical feature of gigantism. Gigantism is caused by excessive secretion of growth hormone (GH) before the epiphyseal growth plates close, leading to excessive linear growth and other systemic effects. While gigantism can cause a variety of physical and metabolic complications, cognitive function, including intelligence, is generally not affected. Thus, mental retardation is not characteristic of this condition. Reasons for Correct and Incorrect Options: A. Mental retardation – Correct (Not seen in gigantism): Mental retardation is not associated with gigantism. GH excess primarily affects somatic growth, skeletal structures, and metabolism, rather than brain development or cognitive abilities. Intelligence is typically normal unless there are other underlying conditions unrelated to GH excess. B. Visceromegaly – Incorrect (Seen in gigantism): Visceromegaly, or the enlargement of internal organs such as the liver, heart, and kidneys, is a well-recognized feature of gigantism. Excess GH and IGF-1 promote growth of not only skeletal structures but also soft tissues and organs, leading to visceromegaly. C. Large foot – Incorrect (Seen in gigantism): Excessive linear growth in gigantism results in disproportionate enlargement of body parts, including hands and feet. Patients with gigantism often present with abnormally large feet and hands due to prolonged growth at the epiphyseal plates before their closure. D. Cardiovascular damage – Incorrect (Seen in gigantism): Cardiovascular complications are common in gigantism and acromegaly due to the systemic effects of prolonged GH and IGF-1 excess. These complications include hypertension, cardiomegaly, left ventricular hypertrophy, and increased risk of heart failure, which contribute to significant morbidity and mortality.",
      "correct_choice_id": 237039,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58936901704444812/58936901704444812.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58936901704444812/58936901704444812.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50978,
      "choices": [
        {
          "id": 237043,
          "text": "Glucoma"
        },
        {
          "id": 237044,
          "text": "Goitre"
        },
        {
          "id": 237045,
          "text": "Jaw malocclusion"
        },
        {
          "id": 237046,
          "text": "Macroencephaly"
        }
      ],
      "text": "Which of the following is not a clinical feature of Acromegaly",
      "unique_key": "Q3413062",
      "question_audio": null,
      "question_video": null,
      "map_id": 34730429,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Macroencephaly. Macroencephaly (abnormally large brain size) is not a clinical feature of acromegaly. While acromegaly is characterized by the overgrowth of bones, soft tissues, and organs due to excessive growth hormone (GH) and insulin-like growth factor 1 (IGF-1), it does not cause an increase in brain size. Skull and facial bone enlargement are common, but the brain's size and structure remain unaffected. Reasons for Correct and Incorrect Options: A. Glaucoma – Incorrect (Seen in acromegaly): Glaucoma can occur in acromegaly due to increased intraocular pressure, which may be associated with soft tissue overgrowth around the orbit or changes in the optic structures. Acromegaly is also associated with an increased risk of visual complications, such as bitemporal hemianopia caused by compression of the optic chiasm from a pituitary adenoma. B. Goitre – Incorrect (Seen in acromegaly): Goitre (enlargement of the thyroid gland) is a well-recognized feature of acromegaly. This occurs due to IGF-1-mediated growth of thyroid tissue. Additionally, acromegaly is associated with an increased prevalence of thyroid nodules and, in some cases, thyroid dysfunction. C. Jaw malocclusion – Incorrect (Seen in acromegaly): Jaw malocclusion, or misalignment of the teeth, is a common feature of acromegaly. It results from mandibular overgrowth (prognathism), causing the lower jaw to protrude and teeth to misalign. This feature is often associated with the characteristic coarse facial features of acromegaly. D. Macroencephaly – Correct (Not seen in acromegaly): Although acromegaly causes skull enlargement, this is due to thickening of the cranial bones rather than an increase in brain size. Macroencephaly refers to an abnormally large brain and is not a feature of acromegaly. The increase in head size in acromegaly is purely skeletal.",
      "correct_choice_id": 237046,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28463701704444826/28463701704444826.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28463701704444826/28463701704444826.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50979,
      "choices": [
        {
          "id": 237047,
          "text": "Often clinically not diagnosed for 10 years or more."
        },
        {
          "id": 237048,
          "text": "Without treatment survival is reduced by 10 years."
        },
        {
          "id": 237049,
          "text": "Hypertension occur in about 75 % of patients"
        },
        {
          "id": 237050,
          "text": "Diabetes mellitus develops in 25 % of patients"
        }
      ],
      "text": "Which of the following regarding acromegaly is false?",
      "unique_key": "Q6415255",
      "question_audio": null,
      "question_video": null,
      "map_id": 34470668,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Hypertension occurs in about 75% of patients. This statement is false because hypertension is observed in approximately 30-40% of patients with acromegaly, not 75%. The hypertension in acromegaly is multifactorial, often related to sodium retention, increased plasma volume, and vascular changes caused by growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess. While hypertension is a common complication, its prevalence does not reach the 75% threshold. Reasons for Correct and Incorrect Options: A. Often clinically not diagnosed for 10 years or more – Correct: This is true because acromegaly typically develops insidiously, with symptoms appearing gradually over years. Many patients remain undiagnosed for a decade or longer, as early signs such as soft tissue swelling, coarse facial features, or joint pain are subtle and often overlooked. By the time acromegaly is diagnosed, significant complications may already be present. B. Without treatment survival is reduced by 10 years – Correct: This is true. Untreated acromegaly significantly reduces life expectancy, primarily due to complications such as cardiovascular disease, diabetes mellitus, and respiratory issues. Studies show that untreated patients have a reduced survival of approximately 10 years compared to the general population. C. Hypertension occurs in about 75% of patients – Incorrect: As mentioned, this statement is false because the prevalence of hypertension in acromegaly is around 30-40%, not 75%. While common, hypertension is not as widespread as implied in the statement. It is essential to manage hypertension in these patients to reduce the risk of cardiovascular complications. D. Diabetes mellitus develops in 25% of patients – Correct: This is true. Acromegaly is associated with insulin resistance caused by the antagonistic effects of GH on insulin action. As a result, glucose metabolism is impaired, leading to diabetes mellitus in approximately 20-30% of patients. Additionally, many patients may develop impaired glucose tolerance or other signs of metabolic dysfunction.",
      "correct_choice_id": 237049,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72911511704444839/72911511704444839.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72911511704444839/72911511704444839.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50980,
      "choices": [
        {
          "id": 237051,
          "text": "Pitutary diabetes insipidus"
        },
        {
          "id": 237052,
          "text": "Nephrogenic DI"
        },
        {
          "id": 237053,
          "text": "Empty sella who do not have DI"
        },
        {
          "id": 237054,
          "text": "All the above"
        }
      ],
      "text": "Pitutary bright spot is absent in patients with?",
      "unique_key": "Q8861972",
      "question_audio": null,
      "question_video": null,
      "map_id": 34936448,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. While the absence of the pituitary bright spot is a classic finding in pituitary diabetes insipidus, it can also be absent in the other conditions listed, which is a key point in more advanced understanding of pituitary imaging. Why the Bright Spot Can Be Absent in All Cases A. Pituitary Diabetes Insipidus (DI): This is the most common and direct cause. The pituitary bright spot represents stored vasopressin (ADH). In pituitary DI, the inability to produce or release ADH directly leads to a lack of stored hormone, and therefore, no bright spot on MRI. B. Nephrogenic DI: While nephrogenic DI is a problem with the kidneys' response to ADH and not ADH production itself, studies have shown that the bright spot can be absent in some cases. The reason for this is not fully understood, but it might be related to a continuous, uninhibited release of ADH from the pituitary in an attempt to compensate for the kidney's non-responsiveness. The lack of ADH storage causes the bright spot to disappear, even though the body is producing the hormone. C. Empty Sella Who Do Not Have DI: The \"empty sella\" refers to an MRI finding where the pituitary gland is compressed or flattened against the walls of the sella turcica. This is often caused by a herniation of the arachnoid membrane and cerebrospinal fluid (CSF) into the sella. In these cases, even if there's no diabetes insipidus, the posterior pituitary gland can be so compressed or anatomically distorted that the characteristic bright spot isn't visible on the MRI. This is a common finding and demonstrates that the bright spot's absence doesn't always indicate a functional hormonal problem.",
      "correct_choice_id": 237054,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14994011704444894/14994011704444894.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14994011704444894/14994011704444894.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50981,
      "choices": [
        {
          "id": 237055,
          "text": "Colon"
        },
        {
          "id": 237056,
          "text": "Lung"
        },
        {
          "id": 237057,
          "text": "Prostate"
        },
        {
          "id": 237058,
          "text": "Gastric"
        }
      ],
      "text": "A 45 year old male presented with features of acromegaly. He is c/o tiredness and easy dyspnea for last 6 months. On examination besides acromegaly, thyromegaly and macroglossia also present. On lab tests IGF levels are increased and glucose fails to suppress growth hormones. MRI pituitary showed growth. Patient is also concerned about cancer as there is family history of cancer present. What cancer should you test the patient for?",
      "unique_key": "Q4081517",
      "question_audio": null,
      "question_video": null,
      "map_id": 34127049,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Colon. This patient with acromegaly and an elevated IGF-1 level confirmed by MRI showing a pituitary growth is diagnosed with acromegaly due to a pituitary adenoma. Acromegaly is associated with an increased risk of colorectal cancer and colonic polyps. This is due to the excess growth hormone (GH) and its indirect effects through IGF-1, which can promote cell growth and increase the risk of malignancies, particularly in the colon. The increased risk of colon cancer is well-documented in patients with acromegaly, and these patients should be regularly screened for colorectal cancer with colonoscopy. Incorrect Options: B. Lung – Incorrect: While lung cancer can occur in general populations, it is not specifically associated with acromegaly. There is no strong link between acromegaly and lung cancer. The patient's family history of cancer could influence the risk of lung cancer, but it is not the most likely malignancy related to acromegaly. C. Prostate – Incorrect: There is no well-established direct link between prostate cancer and acromegaly. While some studies have suggested a potential association between growth hormone and prostate cancer, it is not as strongly supported or prevalent as the association with colon cancer. Therefore, prostate cancer screening is not the primary concern in this patient with acromegaly. D. Gastric – Incorrect: Gastric cancer is not specifically associated with acromegaly. Although acromegaly may have indirect effects on various tissues due to excess growth hormone, the increased risk of gastric cancer is not a well-established feature of the condition. The most relevant cancer screening for a patient with acromegaly would focus on the colon rather than the stomach.",
      "correct_choice_id": 237055,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20577041705044261/20577041705044261.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20577041705044261/20577041705044261.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50982,
      "choices": [
        {
          "id": 237059,
          "text": "Hyperlipidemia"
        },
        {
          "id": 237060,
          "text": "Carpal tunnel"
        },
        {
          "id": 237061,
          "text": "Cardiomyopathy"
        },
        {
          "id": 237062,
          "text": "Joint abnormality"
        }
      ],
      "text": "A 30 year old man presented with complaints of increasing size of hands and feet, hoarseness of voice, excessive snoring. He also c/o dyspnea on exertion and numbness/tingling sensation in hands. On examination acromegaly present and enlarged tongue. Lab results showed elevated IGF, high Hba1c and dyslipidemia. MRI brain showed pituitary adenoma. Surgery is planned for the patient. Patient is asking for results after surgery. Which of the following will most likely resolve after removing the pituitary gland?",
      "unique_key": "Q2731730",
      "question_audio": null,
      "question_video": null,
      "map_id": 34071378,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Because the high lipid level results from the antiinsulin effect of GH, it will likely resolve after the GH is decreased. The other problems are from a permanent growth of protein and will not “resorb” after the GH and IGF levels drop. Additional therapies to lower GH and IGF levels are Pegvisomant, Octreotide and Cabergoline Clinical pearl Pegvisomant is a direct GH receptor antagonist.",
      "correct_choice_id": 237059,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14779931705044279/14779931705044279.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14779931705044279/14779931705044279.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50983,
      "choices": [
        {
          "id": 237063,
          "text": "Estrogen deficiency"
        },
        {
          "id": 237064,
          "text": "Addison disease"
        },
        {
          "id": 237065,
          "text": "Cushing syndrome"
        },
        {
          "id": 237066,
          "text": "Hypothyroidism"
        }
      ],
      "text": "A 34-year-old woman comes to of ice with abnormal milk production from her breasts for the last few weeks. She did three home pregnancy tests and all are negative. She has been unsuccessfully trying to get pregnant for 2 years. Her menstrual periods are irregular. PMHX: Depression Medications: Fluoxetine PE: Normal except galactorrhea. Lab test shows elevated prolactin levels. Which of the following endocrinopathies is associated with high prolactin level?",
      "unique_key": "Q1076852",
      "question_audio": null,
      "question_video": null,
      "map_id": 34276426,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Hypothyroidism. In this patient, galactorrhea (abnormal milk production) and elevated prolactin levels are prominent symptoms. The underlying cause of elevated prolactin in this patient is likely hypothyroidism. Hypothyroidism can cause increased prolactin secretion due to an elevation in thyrotropin-releasing hormone (TRH). TRH stimulates the pituitary gland to secrete prolactin. Additionally, low levels of thyroid hormone result in impaired feedback regulation of TRH and prolactin secretion, leading to hyperprolactinemia. This explains the patient's elevated prolactin levels and galactorrhea. Incorrect Options: A. Estrogen deficiency – Incorrect: While estrogen plays a role in prolactin secretion, estrogen deficiency alone is not a direct cause of elevated prolactin. In conditions like menopause or ovarian failure, estrogen levels drop, but they do not directly lead to significant hyperprolactinemia. Estrogen deficiency may contribute to menstrual irregularities, but it is not the primary cause of elevated prolactin levels in this patient. B. Addison disease – Incorrect: Addison's disease (primary adrenal insufficiency) involves inadequate production of adrenal hormones (such as cortisol and aldosterone). While Addison's disease can cause various symptoms, it is not typically associated with elevated prolactin levels. Instead, Addison's disease primarily affects electrolyte balance, blood pressure, and energy metabolism, rather than directly impacting prolactin secretion. C. Cushing syndrome – Incorrect: Cushing syndrome is caused by excessive levels of cortisol, either from the adrenal glands or from exogenous corticosteroid use. Although Cushing syndrome can cause menstrual irregularities and infertility, it is not commonly associated with elevated prolactin levels. In fact, Cushing syndrome usually results in a reduced prolactin secretion due to the negative feedback effect of high cortisol levels on the pituitary.",
      "correct_choice_id": 237066,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37394391705044340/37394391705044340.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37394391705044340/37394391705044340.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50984,
      "choices": [
        {
          "id": 237067,
          "text": "Refer to neurosurgery"
        },
        {
          "id": 237068,
          "text": "Radiation treatment"
        },
        {
          "id": 237069,
          "text": "Bromocriptine"
        },
        {
          "id": 237070,
          "text": "Cabergoline"
        }
      ],
      "text": "A young female presented with infertility and excess milk discharge from breasts. She is not taking any medications.There is no significant past or family medical history.Lab tests-Plasma glucose 80 mg/dl,Liver and kidney functions are normal,TSH- 3.0 mIU/L,Pooled prolactin levels are high. An MRI pituitary is done which shows a 5-mm lesion in the pituitary gland. What is the next best step?",
      "unique_key": "Q8970944",
      "question_audio": null,
      "question_video": null,
      "map_id": 34531572,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C)",
      "correct_choice_id": 237069,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57614901705044357/57614901705044357.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57614901705044357/57614901705044357.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50985,
      "choices": [
        {
          "id": 237071,
          "text": "Surgery"
        },
        {
          "id": 237072,
          "text": "Radiation"
        },
        {
          "id": 237073,
          "text": "Octreotide"
        },
        {
          "id": 237074,
          "text": "Observation"
        }
      ],
      "text": "In continuation with previous clinical vignette patient was diagnosed as acromegaly. MRI pituitary revealed macroadenoma. What will be the main therapeutic options for him?",
      "unique_key": "Q2389123",
      "question_audio": null,
      "question_video": null,
      "map_id": 34518783,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Surgery. The patient has been diagnosed with acromegaly due to a pituitary macroadenoma. The first-line treatment for acromegaly caused by a pituitary adenoma is usually surgical resection of the tumor. Transsphenoidal surgery is the preferred method to remove the pituitary tumor, especially if it is accessible and if the adenoma is the primary cause of excess growth hormone secretion. Surgery is the most effective treatment for achieving normal growth hormone levels and addressing symptoms associated with the tumor. Incorrect Responses: B. Radiation – Incorrect: Radiation therapy is considered for patients who cannot undergo surgery or who do not respond well to surgery and medical treatment. It is not the first-line treatment because it is slower to reduce growth hormone levels compared to surgery or medical therapy. Radiation may be used in cases of residual disease or inoperable tumors, but it is not the main therapeutic option. C. Octreotide – Incorrect: Octreotide is a somatostatin analog that inhibits growth hormone secretion. While it is an important medical therapy for acromegaly, especially for patients who are not candidates for surgery or who have residual disease after surgery, it is not the first-line option. It is used when surgery cannot completely remove the tumor or if surgery is not an option. In this patient with a macroadenoma, surgery remains the first step in treatment. D. Observation – Incorrect: Observation is not an appropriate treatment for acromegaly caused by a pituitary adenoma. The condition is progressive and requires active treatment to reduce growth hormone secretion and prevent further complications. Observation might be considered in cases of non-functional pituitary adenomas or very small tumors, but it is not a strategy for managing acromegaly.",
      "correct_choice_id": 237071,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78227521705044891/78227521705044891.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78227521705044891/78227521705044891.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50986,
      "choices": [
        {
          "id": 237075,
          "text": "Myxedema"
        },
        {
          "id": 237076,
          "text": "Decreased melanin pigmentation"
        },
        {
          "id": 237077,
          "text": "Emaciation and cachexia"
        },
        {
          "id": 237078,
          "text": "Amenorrhea"
        }
      ],
      "text": "A 25-year-old female presented 12 months after delivery. She complaints of weakness, loss of axillary and pubic hairs. She has amenorrhea for last 5 months. On examination pallor is present along with myxedema features. She is emaciated and cachexic. BP-88/60 mmHg,pulse-58/minute. Chest and CVS examination are normal. You are suspecting pituitary hyposecretion. Which of the following is the most common presentation of anterior pituitary hyposecretion in this female?",
      "unique_key": "Q3639782",
      "question_audio": null,
      "question_video": null,
      "map_id": 34093061,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Amenorrhea. This patient presents with a classic set of symptoms suggestive of hypopituitarism (anterior pituitary hyposecretion), including weakness, loss of axillary and pubic hairs, amenorrhea for 5 months, and myxedema features. Hypopituitarism can lead to the deficiency of several hormones, including gonadotropins (LH and FSH), which regulate the menstrual cycle. The most common and early manifestation of anterior pituitary hyposecretion in women is amenorrhea due to a decreased secretion of gonadotropins, which leads to anovulation and menstrual cessation. The lack of estrogen production also explains the loss of secondary sexual characteristics, such as axillary and pubic hair. Incorrect Responses: A. Myxedema – Incorrect: Myxedema is typically associated with hypothyroidism, which can result from primary thyroid dysfunction or secondary hypothyroidism due to pituitary disease (insufficient TSH secretion). However, in this case, while myxedema features are present (suggesting thyroid hormone deficiency), amenorrhea and other signs of pituitary insufficiency (such as loss of axillary and pubic hairs) are more indicative of pituitary hyposecretion. The thyroid dysfunction may be secondary to pituitary disease, but the primary manifestation of anterior pituitary hyposecretion would be amenorrhea rather than myxedema. B. Decreased melanin pigmentation – Incorrect: Decreased melanin pigmentation is associated with adrenal insufficiency (as in Addison's disease), which results in ACTH overproduction due to low cortisol levels, leading to increased melanocyte stimulation and hyperpigmentation. In this patient, the symptoms of hypopituitarism (particularly the loss of secondary sexual characteristics and amenorrhea) are more indicative of a gonadotropic and thyroid-stimulating hormone deficiency than a disorder affecting pigmentation. C. Emaciation and cachexia – Incorrect: While emaciation and cachexia are concerning symptoms, they are generally more characteristic of severe pituitary hormone deficiencies, such as ACTH deficiency leading to adrenal insufficiency or growth hormone deficiency. These features could be seen in advanced cases of hypopituitarism, but amenorrhea is the most common and early manifestation of anterior pituitary hyposecretion in females. The patient is likely experiencing weight loss due to thyroid hormone deficiency (myxedema), but the primary concern is amenorrhea due to gonadotropin insufficiency.",
      "correct_choice_id": 237078,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2265261705047316/2265261705047316.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2265261705047316/2265261705047316.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50987,
      "choices": [
        {
          "id": 237079,
          "text": "Estrogen receptor defect"
        },
        {
          "id": 237080,
          "text": "Excess hormone production"
        },
        {
          "id": 237081,
          "text": "Androgen receptor defect"
        },
        {
          "id": 237082,
          "text": "Decreased hormone production"
        }
      ],
      "text": "A 19-year-old woman presents with primary amenorrhea. Her physical examination is normal, and she has female sex characteristics and breast development. The only abnormality is the absence of body hair. Genetic testing reveals an XY chromosome pattern. Which of the following mechanisms is most likely to explain her phenotypic pattern and amenorrhea?",
      "unique_key": "Q8562867",
      "question_audio": null,
      "question_video": null,
      "map_id": 34616052,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Androgen receptor defect. This patient presents with primary amenorrhea, female secondary sex characteristics, and breast development, but absence of body hair and an XY chromosome pattern. These findings are suggestive of Androgen Insensitivity Syndrome (AIS), also known as Testicular Feminization Syndrome. In AIS, individuals have an XY karyotype, meaning they have male chromosomes, but they have a defective androgen receptor. This leads to an inability of the body to respond to androgens (male hormones), such as testosterone, which results in a feminized appearance with normal breast development and external genitalia resembling a female. Despite the presence of internal testes (which produce testosterone), the lack of androgen receptor function causes the body to not respond to these hormones, leading to amenorrhea (because there is no estrogen production from the ovaries, which are absent in AIS) and absence of body hair. Incorrect Responses: A. Estrogen receptor defect – Incorrect: An estrogen receptor defect would affect the body’s ability to respond to estrogen, but it would not explain the presence of female external genitalia and breast development in a person with an XY karyotype. Estrogen receptor defects are typically seen in conditions like testicular feminization syndrome with an additional component of estrogen resistance, but the cause in this case is better explained by androgen insensitivity rather than estrogen receptor dysfunction. B. Excess hormone production – Incorrect: Excess hormone production, especially of androgens, is more commonly associated with conditions like congenital adrenal hyperplasia (CAH) or polycystic ovary syndrome (PCOS), which might result in masculinization of external genitalia and amenorrhea, but this would not explain an XY chromosome pattern with normal female secondary sex characteristics. Additionally, excess hormone production would typically lead to hirsutism or virilization rather than the absence of body hair seen in this patient. D. Decreased hormone production – Incorrect: Decreased hormone production typically leads to hypogonadism or gonadal dysfunction, which could cause primary amenorrhea. However, this patient has a feminized appearance with breast development and lacks other signs of hormone deficiency, such as low breast development or absence of female external genitalia. In AIS, the internal testes produce testosterone in normal amounts, but the body cannot respond to it, leading to a lack of gonadal function in terms of sexual development, but not due to a decrease in hormone production.",
      "correct_choice_id": 237081,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24505091705047329/24505091705047329.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24505091705047329/24505091705047329.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50988,
      "choices": [
        {
          "id": 237083,
          "text": "Maturation of the follicle"
        },
        {
          "id": 237084,
          "text": "Encourages progesterone secretion"
        },
        {
          "id": 237085,
          "text": "Causes the secretory phase of the uterine mucosa"
        },
        {
          "id": 237086,
          "text": "Inhibits estrogen secretion"
        }
      ],
      "text": "A 29-year-old woman presents in OPD with complaints of irregular periods and infertility. Her clinical examination is entirely normal. No features of any genetic disorder seen. Biochemical tests show a reduced estradiol and follicle stimulating hormone (FSH) levels. You made a diagnosis of central hypogonadism. Which of the following is the most important function of FSH?",
      "unique_key": "Q6153777",
      "question_audio": null,
      "question_video": null,
      "map_id": 34282689,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Maturation of the follicle. Follicle-stimulating hormone (FSH) plays a crucial role in the female reproductive system, primarily by stimulating the growth and development of ovarian follicles. FSH acts on the granulosa cells of the ovarian follicles, leading to the maturation of these follicles and the production of estradiol. This is essential for the proper functioning of the menstrual cycle and fertility. In the scenario described, the woman is diagnosed with central hypogonadism, which indicates a dysfunction in the hypothalamic or pituitary axis, leading to reduced secretion of FSH and estradiol. The reduced FSH level in this case impairs the normal maturation of ovarian follicles, which can result in irregular periods and infertility. Incorrect Responses: B. Encourages progesterone secretion – Incorrect: FSH does not directly encourage the secretion of progesterone. Progesterone is primarily secreted by the corpus luteum in response to luteinizing hormone (LH), not FSH. While FSH is important in the earlier stages of the menstrual cycle for follicle maturation, LH is the hormone responsible for triggering ovulation and stimulating progesterone secretion from the corpus luteum. C. Causes the secretory phase of the uterine mucosa – Incorrect: The secretory phase of the uterine cycle is regulated by progesterone, not FSH. After ovulation, progesterone released by the corpus luteum transforms the uterine lining into a secretory state in preparation for a potential pregnancy. FSH's main role is follicle maturation and estradiol production, which is necessary for the proliferative phase of the endometrium, not the secretory phase. D. Inhibits estrogen secretion – Incorrect: FSH does not inhibit estrogen secretion. In fact, FSH stimulates the granulosa cells of the ovaries to produce estradiol (a form of estrogen), which is essential for follicular development and regulation of the menstrual cycle. Estradiol, in turn, provides feedback to the hypothalamus and pituitary gland to regulate FSH and LH secretion.",
      "correct_choice_id": 237083,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/22236581705047365/22236581705047365.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/22236581705047365/22236581705047365.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50989,
      "choices": [
        {
          "id": 237087,
          "text": "Hypothalamic tumor"
        },
        {
          "id": 237088,
          "text": "Hyperintense signals in the cerebral cortex"
        },
        {
          "id": 237089,
          "text": "Agenesis of the corpus callosum"
        },
        {
          "id": 237090,
          "text": "Lack of hyperintense signals from the posterior pituitary"
        }
      ],
      "text": "A 50 year old male presented with polyuria and polydipsia.There is no family history of diabetes mellitus.On examination BP-110/80 mmHg.On lab tests urine osmolality is less than 300 which remains low even after fluid deprivation test.After giving desmopressin urine osmolality increased to 500.You made a diagnosis of central diabetes insipidus.You order for MRI of brain. Which of the following is the most likely finding on magnetic resonance imaging of the brain?",
      "unique_key": "Q1444151",
      "question_audio": null,
      "question_video": null,
      "map_id": 34115844,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Lack of hyperintense signals from the posterior pituitary. In central diabetes insipidus (DI), there is a deficiency of antidiuretic hormone (ADH) (also called vasopressin) produced by the hypothalamus and stored in the posterior pituitary. Normally, the posterior pituitary produces high-intensity signals on magnetic resonance imaging (MRI) due to the presence of vasopressin and other proteins. In central DI, the lack of ADH production leads to a reduced or absent hyperintense signal from the posterior pituitary on an MRI scan. Therefore, the most likely finding on MRI in a patient with central diabetes insipidus is the absence of this hyperintense signal from the posterior pituitary. Incorrect Responses: A. Hypothalamic tumor – Incorrect: While hypothalamic tumors can cause central diabetes insipidus by impairing the production of ADH, they are not as common a cause as lesions affecting the posterior pituitary. Moreover, a hypothalamic tumor may not always result in complete absence of the hyperintense signal in the posterior pituitary, which is the characteristic finding of central DI. The MRI finding in central DI is specifically associated with a deficiency in ADH release, which is best visualized by the absence of the hyperintense signal from the posterior pituitary, not by the tumor itself. B. Hyperintense signals in the cerebral cortex – Incorrect: Hyperintense signals in the cerebral cortex are not typical in central diabetes insipidus. Hyperintense signals in the cerebral cortex on MRI are generally associated with conditions such as stroke, seizures, or other neurological abnormalities, rather than central diabetes insipidus. The primary finding in central DI is related to the pituitary gland, specifically the absence of the hyperintense signal in the posterior pituitary. C. Agenesis of the corpus callosum – Incorrect: Agenesis of the corpus callosum refers to the congenital absence or malformation of the structure that connects the two cerebral hemispheres. While agenesis of the corpus callosum can be associated with a variety of neurological and endocrine disorders, it is not a typical finding in central diabetes insipidus. Central DI is primarily related to defects in ADH production or release, not abnormalities in the corpus callosum.",
      "correct_choice_id": 237090,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3170281705047449/3170281705047449.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3170281705047449/3170281705047449.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50990,
      "choices": [
        {
          "id": 237091,
          "text": "Excess growth hormone"
        },
        {
          "id": 237092,
          "text": "Cushing’s disease"
        },
        {
          "id": 237093,
          "text": "Thyrotoxicosis"
        },
        {
          "id": 237094,
          "text": "Tumor of the pancreatic beta-cells"
        }
      ],
      "text": "A 42-year-old woman develops light-headed episodes associated with sweating, palpitations, and hunger whenever she misses a meal. There is no past medical history of diabetes or hypertension. Her physical examination is normal, and she is not taking any medications. On one such episode, while in hospital, her blood glucose level was 30 mg/dL and the symptoms resolved with giving her juice. Which of the following is the most likely diagnosis?",
      "unique_key": "Q2096994",
      "question_audio": null,
      "question_video": null,
      "map_id": 34273280,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Tumor of the pancreatic beta-cells (insulinoma). This patient's symptoms of light-headedness, sweating, palpitations, and hunger, along with the blood glucose level of 30 mg/dL, are suggestive of hypoglycemia. The most likely cause of recurrent hypoglycemic episodes without an underlying history of diabetes is an insulinoma, which is a tumor of the pancreatic beta cells that secretes excessive insulin. This leads to low blood glucose levels, which can cause symptoms such as the ones described by the patient. Treatment of hypoglycemia (e.g., juice) relieves the symptoms, confirming the diagnosis of insulinoma. Incorrect Answers: A. Excess growth hormone: Excess growth hormone can cause acromegaly, which can lead to symptoms like joint pain, large hands and feet, and facial changes. However, it is not typically associated with hypoglycemia or the symptoms described by the patient. In fact, acromegaly is more commonly linked with hyperglycemia due to insulin resistance. B. Cushing’s disease: Cushing's disease, caused by an ACTH-secreting pituitary tumor, leads to hypercortisolism and is associated with weight gain, central obesity, moon face, and muscle weakness. It typically causes hyperglycemia (not hypoglycemia) due to the effects of cortisol on insulin resistance. Thus, it is not a likely cause of the patient's symptoms. C. Thyrotoxicosis: Thyrotoxicosis (hyperthyroidism) can cause symptoms like palpitations, sweating, and weight loss, but it does not typically cause hypoglycemia. It may increase metabolism and lead to some symptoms similar to hypoglycemia, but it is more often associated with elevated blood glucose rather than low glucose levels.",
      "correct_choice_id": 237094,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39587651705047982/39587651705047982.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39587651705047982/39587651705047982.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50991,
      "choices": [
        {
          "id": 237095,
          "text": "Inadequate diet"
        },
        {
          "id": 237096,
          "text": "Normal variation"
        },
        {
          "id": 237097,
          "text": "Pituitary tumor"
        },
        {
          "id": 237098,
          "text": "Leydig cell dysfunction"
        }
      ],
      "text": "A 15-year-old youth presented to OPD with his parents as he has not developed facial hairs. His voice is not hoarse unlike his batchmates in school. His father also gives history of delayed puberty. On examination his axillary hairs are sparse with no facial hairs. His vitals are normal. Blood tests showed normal testosterone and LH levels for his age. Which of the following is the most likely diagnosis?",
      "unique_key": "Q8422161",
      "question_audio": null,
      "question_video": null,
      "map_id": 34363108,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Normal variation Explanation of Correct Answer: The patient presents with delayed puberty, characterized by lack of facial hair and sparse axillary hair. Given that the patient’s testosterone and LH levels are normal for his age, this suggests that the hormonal levels required for puberty are present but that his development may simply be delayed compared to his peers. The fact that his father also has a history of delayed puberty further supports the possibility of a genetic delay in puberty. In many cases, delayed puberty is just a normal variation in development, where individuals experience a later onset of puberty but eventually catch up. The patient’s physical findings and lab results do not point to a pathological cause, making normal variation the most likely diagnosis. Explanation of Incorrect Answers: A. Inadequate diet: An inadequate diet can lead to malnutrition, which might delay puberty by affecting hormonal levels, particularly those related to growth and sexual development. However, this patient's blood tests show normal testosterone and LH levels for his age, which rules out a nutritional cause. Malnutrition would typically result in low testosterone and/or LH levels, which are not seen here, making inadequate diet an unlikely cause. C. Pituitary tumor: A pituitary tumor could affect the production of LH, FSH, or other hormones involved in puberty. However, this patient has normal LH levels, and there is no indication of other symptoms that would suggest a pituitary tumor, such as visual disturbances, headaches, or other hormonal imbalances. A pituitary tumor would likely result in abnormal hormone levels, which are not seen here, making this diagnosis less likely. D. Leydig cell dysfunction: Leydig cell dysfunction leads to low testosterone levels due to impaired production by the Leydig cells in the testes. If this were the case, the patient would likely show low testosterone levels on testing. However, this patient’s testosterone levels are normal, which rules out Leydig cell dysfunction as the cause of his delayed puberty.",
      "correct_choice_id": 237096,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9338351705048265/9338351705048265.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9338351705048265/9338351705048265.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}